Shelf Control: The Cryosite Story (ASX: CTE)

Good morning Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

The most successful storage business of all time started inside a mountain.

Built by a mushroom farmer in 1951.

He had more space than he knew what to do with.

It’s called Iron Mountain, and it's in Upstate New York:

Sony's master recordings, the will of Princess Diana, the original photo of Albert Einstein sticking his tongue out…

All stored at Iron Mountain.

Its largest customer is the US Government.

If aliens exist… 

I bet it would be stored there too.

The business is worth about $38 billion dollars today.

And it prints money.

The reason I’m telling you all of this is to help you understand the principles and framework that make for a great storage business.

Space and reliability. 

I’m not talking about storing old junk like you’d find on an episode of Storage Wars…

(one of the greatest reality shows of all time, I might just add)

I’m talking about important storage of material, where mistakes are not an option.

A full-scale operation that has systems, redundancy and trust.

This is the framework for understanding the next company in my Biotech 165 Challenge: Cryosite (ASX: CTE).

Cryosite is a storage and freezing business for material used in Australian clinical trials (particularly stem cell and CAR-T research).

It’s profitable. 

And quietly 10-bagged over the last 5 years.

But first…

At the 2026 ASCO conference, the crowd gave a massive standing ovation after data were presented showing that daraxonrasib doubled survival among patients with pancreatic cancer.

A moving moment that reminds us why many people are in healthcare and drug development: to save lives.

Watch the video here:

Imagion Biosystems (ASX: IBX) receives FDA clearance for its IND application, allowing Phase 1b/2 clinical trials of MagSense HER2 Imaging Agent for breast cancer to begin. (IBX)

🪑 Nice. IND is important as it allows the company to run clinical trials in the US. 

Also, I appreciated the additional details on the trial design. It looks like there will be a number of stages, with Stage C the most important - efficacy.

Entropy Neurodynamics (ASX: ENP) completes Cohort 1 dosing in its Phase 2 trial of IV-infused psylocin TRP-8803 for Binge Eating Disorder. (ENP)

🪑 Milestone ticked. Top-line efficacy results due next month.

4DMedical (ASX: 4DX) launches a new program to fast-track CT:VQ entry into the pulmonary embolism market. (4DX)

🪑 Think of this like a ‘label extension’ study to expand the market for where 4DX can sell its product. The CT:VQ will go head-to-head with the standard of care.

Osteopore (ASX: OSX) launches a clinical trial with Queensland Children’s Hospital for paranasal augmentation in 5 pediatric patients. (OSX)

🪑 Paranasal Augmentation = Nose Job.

Paradigm Biopharmaceuticals (ASX: PAR) completes oversubscribed Share Purchase Plan, raising $7.375M (target $2M), a total of $21.375M in funding to advance Phase 3 clinical trial. (PAR)

🪑 Trading under SPP price of 17 cents. PAR took every dollar applied, so I imagine there will be some churn.

Most people misunderstand the storage industry.

They think the product is space.

It’s not. 

The product is reliability.

The moment a customer puts something into storage, their incentive flips. 

Before, they're a shopper. 

Comparing prices, playing you off against the other guy, shopping around. 

The second it's inside, catalogued and sitting on your shelf, they become something else entirely…

A hostage to their own decision.

Now the question isn't "who's cheapest?" 

It's "do I really want the hassle, and the risk, of moving this?"

And the answer, almost always, is no.

So you raise the rent. A little, every year. And they pay it. Not because of your service, but because moving the thing is a pain, and the pain grows the longer it sits there.

Great storage businesses don't retain customers. They trap value.

But not all storage is created equal. 

A self-storage unit full of someone's old junk is the weak end of the spectrum. 

The switching cost is real but small.

(might be cheaper to abandon the goods altogether)

But for high-end storage.

That is irreplaceable.

Biomaterial fits into this category.

Especially if it needs to be frozen, at minus-196 degrees and can never be remade. 

Just like the customers at Iron Mountain, reliability is the value proposition.

This brings me to the next company on my Biotech 165 Challenge, Cryosite (ASX: CTE).

I visited the site last month and got a full tour of the business.

While it looks like a giant freezer…

Underneath it all is a system of reliability that has put it in a commanding market position. 

… and a company that has quietly 10-bagged since 2020, without much fanfare or notice.

So, let’s find out what happened.

Cryosite was first listed on the ASX in May of 2002.

It was listed as a cord blood storage business.

The idea was to cryogenically freeze and store the stem cells from newborn babies' umbilical cords, so that later in life they might need them for life-saving treatments.

All of the cash was taken up front (18- or 24-year contracts), which was good when the company launched… but made the business tricky to maintain.

This business lasted for about 15 years.

Until margins were squeezed and Cryosite looked to sell off the umbilical cord storage.

Concerned about the sale to an existing competitor in the space, the ACCC intervened and the deal was abandoned altogether.

(I’ll dive into this detail a bit later)

Even so…

Cryosite stopped collecting new cord blood and transitioned to clinical trials and biological storage across the full temperature spectrum.

Including a niche in ultra-frozen (-80 degrees) and cryogenic (-196 degrees) storage.

This was 2017.

Right about the time that the FDA had approved the first-ever CAR-T cell therapy…

Perfect tailwind for Cryostie.

By late 2021, 75% of Cryosite’s revenue had come from storage of clinical trial material. 

… which led to six straight years of growth. 

As of the last Financial Year, Cryosite had $14.1M in revenue and $3.4M in EBITDA.

Not a bad turnaround.

If you've read my Bioxyne (ASX: BXN) story, you'll know I flew to Brisbane to walk through Australia’s largest GMP facility for medical cannabis.

The story is much the same.

Reliability. Systems. Trust.

After I published that article, I got messages from the Cryosite team saying they had built something very similar. 

Whether you’re making weed gummies or freezing stem cells, GMP businesses all have the same backbone.

Reliability.

As soon as you walk into the Cryosite facility, all the TGA licences are on the wall.

This is Cryosite’s moat.

(Similar to Bioxyne)

It’s about a 3-5 year lead time to get a new licence and a $20 million facility buildout.

Importantly, Cryosite has coverage for “Storage”.

This broad coverage is important, as the TGA is more specific these days.

Gives them an advantage over any new entrant.

If you’ve ever been to one of the IKEA showrooms and have marvelled at how well the process flow operates, that was the exact same feeling that I had at Cryosite’s storage facilities.

Everything just fit.

It starts out at the lorry bay, where biological material is loaded on and off.

We then walked to the area with an ultra-frozen storage facility for stem cells and CAR-T therapies.

The thing with GMP facilities is that you’re space-constrained.

Once you’ve got the licence, and you’ve hit the walls, there is only one more place you can go…

Up.

This was the heart of Cryosites ' ultra-frozen and cryogenic operations.

The stakes are high. 

If the temperature is off just a little bit on a CAR-T dose…

You don’t just lose a customer, but a patient’s only dose.

A personalised therapy manufactured from their own cells that can't simply be re-ordered.

When the product in your freezer is literally irreplaceable. 

Being "reliable" is no longer a nice-to-have, and it is the entire value proposition.

These items have to be incredibly temperature-controlled, and if there is even a slight drop in temperature…

Poof…

There goes the cell therapy.

There are TWO backup generators, in case they lose power:

And every single asset (tanks, freezers, temperature-controlled rooms) is monitored for temperature, sitting right there on a dashboard in the front office.

Even the receptionist keeps an eye on things…

We then moved to the ambient, cold and frozen logistics section of the building.

This is where the bulk of the operations are.

Cold, but not freezing, and where a lot of clinical trial material is stored.

Now, if you’re running a trial, getting the right material into the right patient is paramount.

Any mistakes here and it could ruin the trial (or worse, make the patient sick or die).

Zero mistakes.

That’s the rule.

The systems that Cryosite have in place are thorough. 

Fallbacks upon fallbacks. 

Multiple checks and multiple redundancies to make sure that the right material goes to the right place:

I remember the CEO, Andrew, telling me that another customer went to one of the larger storage facilities, like DHL or Toll, and was back within months because they couldn’t manage temperature control. 

Systems and redundancies.

THAT is the moat that Cryosite has built.

Remember that cord business I mentioned earlier?

The one that was started in 2002 and halted in 2017.

Well, it hasn’t gone away, and now it’s printing money for Cryosite.

It’s stickiest, lowest-effort money… from the business it once tried to sell.

Back in 2017, Cryosite agreed to sell its fledgling cord blood bank to Cell Care, its sole competitor in the space. 

$500,000 upfront for an option, payment on the backend.

But there was a clause in the deal. Cryosite had to send all new customer enquiries straight to Cell Care, before the sale had even closed.

The ACCC took one look and saw two competitors carving up a market between them.

Cartel conduct.

The deal collapsed. And in the first "gun-jumping" case of its kind in this country, the Federal Court fined Cryosite $1.05 million.

Ouch!

At the time, it looked like Cryosite's low point. It was actually the making of the company.

Because the regulator that fined them also forced them to keep an asset they'd written off as dead weight.

Cryosite stopped taking new cord blood collections. 

Original contracts were 18 and 24-year agreements and paid upfront.

(Great cash flow at the start, terrible business towards the end)

But as those old contracts rolled off, Cryosite offered a renewal. 

Rolling annual contracts at $227 a year.

And the take-up rate was much larger than Cryosite expected.

Each year that one of these legacy contracts rolls off, that’s another $227 in annual fees to Cryosite… for no extra work.

Peak in legacy contract expirations are ramping up over the next 5 years.

Cash in pocket with infrastructure that's already paid for.

(and an asset they had written off to zero)

A business, they couldn't wait to sell.

Printing cash.

Cryosite has about 48.8 million shares on issue.

Its last capital raise was done in 2005.

Expansions have been funded from the business's cash flows, with some debt financing, rather than tapping the market.

The register is held by a handful of large shareholders:

That doesn’t leave much free float for trading.

The company has moved from 5 cents at the 2019 lows to over a $1 today.

A quiet 10-bagger, built on earnings, not raisings.

But I have this saying…

No conflict, no interest.

Just because a small group of shareholders manage the register incredibly tightly doesn’t necessarily make for a good investment.

It’s a hard stock to buy and a hard stock to sell.

So many investors put it in the “too hard” bucket.

Okay for mum-and-dad investors with a $5K ticket. But much harder for institutions to get in.

Brokers avoid too.

Without the carrot of a raise, the brokers also have no incentive to go shop this around to their institutional and retail desks.

So every move in the Cryosite share register comes from a small group of tight holders, with a few breadcrumbs in between.

In fact, it's the breadcrumbs that really set the price.

Here is how the stock has traded, and you can see the movements in tiny volumes:

A very tricky, illiquid register.

So, as an investor in Cryosite, it’s a bet on them making meaningful growth in the business.

Without the company trading on potential.

Cryosite has done well to establish a moat in the Australian market for storing biological material for clinical trials over the last few years.

But a moat only makes money if there are growth tailwinds in place.

So where does the growth actually come from?

Three places.

(Plus a big exit potential at the end)

The ultra-frozen segment grew 58% in FY25, driven by cell and gene therapy. 

The CAR-T market alone is heading toward US$4.8 billion in 2026 and is tipped to roughly double by 2031, with Asia-Pacific the fastest-growing slice.

Every one of those therapies needs a cold chain. 

That’s where Cryosites growth will come from.

The current site is running out of space.

So, in FY25, they added a 17% footprint expansion and a 40% lift in ultra-frozen freezer capacity, all funded from cash flow.

(This was the upstairs section)

Then, in November 2025, they bought a freehold warehouse at Auburn, NSW, for $9.5 million.

I went and visited this facility too (about a 20-minute drive away):

A second site isn't just more room. 

For critical clients, splitting samples across two physical locations is the redundancy that wins the contract.

In its AGM presentation last year, Cryosite highlighted one of its strategic priorities as “international partnerships”

For me, this is where the biggest opportunity is.

… but also the biggest risk.

The global cryogenics market is dominated by Cryoport (NASDAQ: CYRX), a NASDAQ-listed company.

The US gorilla is generating US$176 million in revenue, accounting for ~70% of global cell-and-gene clinical trials. 

Storage and reliability are incredibly strong moats, but there are big regulatory hurdles to overcome.

If Cryosite were ever to enter global markets, with no offshore footprint of its own, it may need to partner with or merge with a smaller player with existing facilities.

Just like Byoxine, nothing about Cryosite is proprietary.

All value is derived from the systems and trust built over time.

Entering a new market is incredibly risky, BUT Cryosite likely has ambitions beyond just being a good Australian business.

Cryosite is getting to a point where it is an attractive takeover target for a company like Cryoport (or one of its competitors).

Cryosite already has the systems, customers, and footprint in Australia.

If a larger global player is looking to expand into APAC, Cryosite presents a very good opportunity.

That said, I never like to bank on a takeover for my investments.

It could drop at any time… or never at all.

Cryosite has built a great Australian business on Iron Mountain's two principles.

Space and reliability.

The two things every storage business needs.

But a moat only pays if something's growing behind it. 

For Cryosite, that's the Australian biotech sector, more CAR-T, more stem cells, more frozen biological material that someone has to store.

The catch is the register.

The big holders underpin the value. 

The retail breadcrumbs set the price. 

(Yesterday it was up 10% on $2,500 traded.) 

So the market cap isn't really a price; it's a guess, made by whoever happened to trade last. 

Big money can't get in, holders can't get out. 

(not without tanking the price).

It's the kind of stock most people file under "too hard."

But think back to where we started.

Iron Mountain wasn't always a $38 billion giant. 

It started as a mushroom farmer standing in a hole in the ground, with more empty space than he knew what to do with. 

Freezing things. Storing things. Charging rent on stuff nobody wanted to think about.

Boring. Unglamorous. Easy to overlook.

70 years later and Iron Mountain stores the world's most precious things and prints money doing it.

Cryosite at 5 cents in 2019 was its own hole in the ground. 

A broken little cord-blood company that had just been fined by the regulator.

Today, it's over a dollar, with a moat, a second site, and a tailwind it didn't have to build.

The question was never whether it's a good business.

It's whether you'd have had the patience to sit in something this quiet, this illiquid, this boring… long enough for the rent to compound.

A big thank you to Andrew and the team at Cryosite for showing me through the facility and sharing the story.

See you all tomorrow,

The Armchair Analyst